Table 2 Immune checkpoint inhibitor agent administered by malignancy type
| No. (%) | ||||
|---|---|---|---|---|
| Checkpoint inhibitor |
Melanoma n = 120 |
Solid tumor n = 148 |
Hematologic cancer n = 59 | P |
| Ipilimumab | 81 (68) | 44 (30) | 13 (22) | < 0.001 |
| Nivolumab | 7 (6) | 62 (42) | 31 (53) | |
| Pembrolizumab | 23 (19) | 31 (21) | 15 (25) | |
| Combinationa | 9 (8) | 10 (7) | 0 (0) | |
| Atezolizumab | 0 (0) | 1 (1) | 0 (0) | |